GoodRx reports Q3 adjusted EPS 8c, consensus 9c

Reports Q3 revenue $195.3M, consensus $195.65M. “In a world where there is increasing attention on medicine affordability and access, we believe the strategic high ground belongs to brands and companies that benefit patients and remove friction from a complicated healthcare ecosystem. At GoodRx (GDRX), that’s our North Star and we believe it’s enabled us to gain share in our category and strengthen our value proposition throughout 2024,” said Scott Wagner, Interim Chief Executive Officer of GoodRx. “We continue to build momentum on our programs with brand manufacturers and anticipate about 20% year-over-year top-line growth in our pharma manufacturer solutions offering for Q4 2024, and 20%+ for full year 2025. And while the retail pharmacy environment is experiencing short-term choppiness, we believe we continue to provide invaluable support to our partners by driving traffic and helping them meet their merchandising goals.”